Search Results

December 2021 OMass Therapeutics's founder, Carol Robinson, has been awarded the prestigious Louis-Jeantet Franklin Medal in Chemistry from The Franklin Institute yesterday for contributions to the field of mass

November 2021 "Nov. 15, 2021 LONDON – There’s not yet proof of the pudding, but Omass Therapeutics Ltd

Chemistry, former president of the Royal Society of Chemistry and Founder of (and ongoing consultant to) OMass Therapeutics, which is based at Oxford Science Park, has been awarded the 2022 Louis-Jeantet Prize for

Clinical insights on tachyphylaxis, tolerance, and kinetic-based therapeutics. < Back How Signaling Kinetics kinetics, the temporal dynamics of receptor activation and downstream signaling, directly influence therapeutic spans tachyphylaxis mechanisms in beta-agonist therapy, tolerance development with opioid agonists, and therapeutic pharmacologists, drug discovery scientists, and translational researchers working on temporal aspects of GPCR therapeutics specializing in kinetic analysis of drug action and the application of binding and signaling kinetics to therapeutic

Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic